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Division of Clinical
To the Editor: El-Omar et al. (1 ) reported that interleukin (IL)-1 gene cluster variants that enhance the production of IL-1␤ (a powerful inhibitor of gastric acid secretion) increase the risk of gastric cancer in Helicobacter pylori (HP)-infected patients. IL-1␤ production is down-regulated by mannose-binding lectin (MBL) (2 ) , an acute-phase glycoprotein that has a high affinity for gram-negative lipopolysaccharide and exerts immunological activity (3, 4 ) . Variants in the promoter, the 5ЈUTR, and exon 1 of the MBL2 gene reduce the synthesis and activity of MBL (5 ) .
To assess the relationships between MBL2 gene variants and HPrelated gastric cancer, we analyzed the whole coding region and the 5ЈUTR of the MBL2 gene in DNA extracted (QIAamp, Qiagen) from neoplastic cells embedded in paraffin sections (used for histological diagnosis) from 145 unrelated patients (90 males) affected by noncardia gastric cancer. Eighty-seven (60.0%) had intestinal-type; 47 (32.4%), diffusetype; and 11 (7.6%), mixed-type adenocarcinoma. All patients had HPpositive serology. For 75 patients, we also analyzed DNA extracted from blood or from nonneoplastic surrounding tissue. All participants gave informed consent.
We examined DNA extracted from blood of 553 (240 males) unselected, unrelated, healthy adults from Southern Italy. For each DNA sample, we sequenced the promoter (Ϫ550 to Ϫ221), 5ЈUTR (Ϫ464 to ϩ104), and exon 1 (Ϫ97 to ϩ206) of the MBL2 gene in both directions. Primers, PCR mix, and conditions are available on request. MBL2 mutations in exon 1 at codons 54, 52, and 57 are called B, D, and C, respectively (5 ). The wild-type allele is "allele A". The 3 polymorphisms in the promoter region are called H/L (Ϫ550), X/Y (Ϫ221), and P/Q (ϩ4 in the 5ЈUTR).
Analysis results for DNA from blood or from nonneoplastic tissue of 75 patients with gastric cancer invariably were the same as those for neoplastic tissue, excluding the possibility that MBL2 haplotypes were altered by somatic mutations. complexes and reducing the immunological activity of the protein (4 ) . Participants bearing the D allele in heterozygosis (9 gastric cancer patients in the present study; Table 1 , part B) have a 10-fold lower serum MBL concentration, and the immunological activity of the residual protein is very low because of impaired polymerization. Homozygotes for the D allele (3 gastric cancer patients in the present study; Table 1 , part B) have no residual activity of the protein (5 ).
We suggest that the low MBL activity in patients bearing the HYPD haplotype may allow enhanced bacterial colonization of the gastric mucosa and reduce down-regulation of IL-1␤ production, thereby increasing the risk of gastric cancer (odds ratio: 2.5; Table 1 , part A). Indeed, IL-1␤ production is up-regulated by HP. IL-1␤ induces chronic hypochlorhydria, which promotes the spread of HP-induced inflammation and leads to gastric atrophy, a precursor of gastric cancer (1 ) . Hypochlorhydria also promotes the colonization of other bacteria that foster mucosal damage and the production of carcinogenic compounds (1 ), adding to the scarce antibacterial activity of MBL caused by the HYPD haplotype. IL-1 gene polymorphisms that enhance IL-1␤ production are associated with an increased risk of gastric cancer in HPinfected patients (1 ) . Furthermore, the addition of sera containing unaffected MBL concentrations to monocytes stimulated by N. meningitidis downregulates the production of IL-1␤, whereas the addition of sera from MBL-deficient individuals enhances the production of the cytokine (4 ). Otherwise, MBL2 HYPD haplotype may be in linkage disequilibrium with variants of other genes responsible for the increased risk of gastric cancer.
To conclude, the MBL2-defective HYPD haplotype may be a novel genetic marker of risk for gastric cancer in HP-infected patients. 
Assay Interferences from Blood Collection Tubes: A Cautionary Note
To the Editor: Recent publications (1, 2 ) have reported an association between the surfactant present in BD Vacutainer® blood collection tubes and interference in select immunoassays on certain instrument platforms. Blood collection tubes contain not only surfactants but multiple additives that contribute to the optimal recovery of serum or plasma for laboratory analysis. For plastic tubes, which are largely replacing glass tubes because of safety considerations, several suppliers have added silica particles to promote blood clotting (3) (4) (5) and polyvinylpyrrolidone to aid the adherence of silica particles to the tube walls and to facilitate rapid dissolution of the silica in the blood specimen. Moreover, siliconebased surfactants or polypropylene oxide are present as coatings for the interior tube wall (6, 7 ) to act as hemorepellent agents and improve blood flow. Stoppers of tubes are also coated with lubricant to facilitate their removal and to maintain the lower pressure inside the evacuated tubes (4 ). Separator gels are present in some tubes to serve as a barrier between the serum (or plasma) and the clot after centrifugation of the tubes (8 ) . Plastic blood collection tubes have been widely shown to be suitable for routine clinical chemistry analytes, hormone analysis, and therapeutic drug monitoring (9 -11 ) .
Surfactants are also a common component of many immunoassays. They are used to decrease or eliminate nonspecific adsorption, improve stability of the reagents, or modify the solid-phase surface to render it less hydrophobic and thus minimize loss of noncovalently bound antibody. Inclusion of surfactants in immunoassay reagents requires careful selection and optimization. High concentrations of surfactants may lead to direct loss of passively adsorbed antibody from the solid phase, among other nonspecific effects (12) (13) . The reports by Bowen et al. (1, 2 ) show that a high concentration of a silicone-based surfactant is a potential source of the immunoassay interference in the DPC IMMULITE ® 2500 Total Triiodothyronine (TT 3 ) assay. The authors indicate that one of the possible mechanisms of interference is desorption of the antibodies from the solid phase by the surfactant for the TT 3 assay (1 ), resulting in a falsely increased estimate of the TT 3 concentration. As described above, this phenomenon is not unknown in immunoassays in which the antibodies are passively adsorbed onto the solid phase (12) (13) . Other types of assay formats with more robust antibody binding schemes do not show this problem, even at high concentrations of surfactant as demonstrated on the AxSym™ analyzer. The concentration of surfactant at which Bowen et al. demonstrated the desorption of antibody in the TT 3 assay was 2-to 24-fold higher than the concentration of surfactant per milliliter of blood present in the BD Vacutainer tubes that exhibited the interference in the TT 3 assay. The current adjusted BD Vacutainer tubes have been shown to produce no clinically significant differences for a variety of assays across many instrument platforms when compared with competitive products [see "Note added in proof" in reference (2 ) ]. The concentration of the surfactant has been adjusted to decrease any known assay interferences and yield clinically equivalent results compared with glass tubes (14 ) .
Assay interferences from blood collection tubes can present challenges to clinical laboratories because they are not easily detected by the daily quality control or even by proficiency testing programs because the samples for such testing are not exposed to the additives in the blood collection tubes (15 ). However, it is always good practice for laboratories to monitor their reference intervals and population trends and report deviations to the device manufacturers. All laboratorians should be vigilant for potential effects on laboratory assays and work together in partnership with tube manufacturers and diagnostic companies to prevent and minimize problems.
